PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Kim, Hye Ryun ^a   Ha, Sang Jun ^b   Hong, Min Hee ^a   Heo, Su Jin ^a   Koh, Yoon Woo ^c   Choi, Eun Chang ^c   Kim, Eun Kyung ^c   Pyo, Kyoung Ho ^d   Jung, Inkyung ^c   Seo, Daekwan ^c   Choi, Jaewoo ^c   Cho, Byoung Chul ^a,d   Yoon, Sun Och ^c  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

^d JE UK Institute for Cancer Research Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1;

ADULT; AGED; CANCER STAGING; CD8+ T LYMPHOCYTE; FEMALE; GENE EXPRESSION REGULATION; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL ANALYSIS; TUMOR ASSOCIATED LEUKOCYTE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; B7-H1 ANTIGEN; CARCINOMA, SQUAMOUS CELL; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84995390559     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36956     Document Type: Article

References (41)

1. Straub, M. et al. CD274/PD-L1 gene amplification and PD-L1 protein expression are common events in squamous cell carcinoma of the oral cavity. Oncotarget, doi:10.18632/oncotarget.7593. 102024-112034 (2016).
2. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567 (2014).
3. Swanson, M. S. & Sinha, U. K. Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer-review of current data. Oral Oncol. 51, 12-15 (2015).
4. Kim, J. W. & Eder, J. P. Prospects for targeting PD-1 and PD-L1 in various tumor types. Oncology 28 Suppl 3, 15-28 (2014).
5. Fury, M., Ou, S. I., Balmanoukian, A. & Hansen, A. Clinical activity and safety of MEDI4736, an anti PD-L1 antibody, in patients with head and neck cancer [abstract 988PD]. Ann Oncol 25, iv340-iv356 (2014).
6. Segal, N. H. et al. Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. J. Clin. Oncol. 32, 3002 (2014).
7. Seiwert, T. Y. et al. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J. Clin. Oncol. 32, 6011 (2014).
8. Ferris, R. L. Immunology and immunotherapy of head and neck cancer. J. Clin. Oncol. 33, 3293-3304 (2015).
9. Teng, M. W., Ngiow, S. F., Ribas, A. & Smyth, M. J. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 75, 2139-2145 (2015).
10. Ock, C. Y. et al. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration. Clin. Cancer Res. 22, 2261-2270 (2016).
11. Partlova, S. et al. Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. Oncoimmunology 4, e965570 (2015).
12. Strauss, L. et al. The frequency and suppressor function of CD4+ CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13, 6301-6311 (2007).
13. Camisaschi, C. et al. LAG-3 expression defines a subset of CD4(+)CD25(high)Foxp3(+) regulatory T cells that are expanded at tumor sites. J. Immunol. 184, 6545-6551 (2010).
14. Ferris, R. L., Lu, B. & Kane, L. P. Too much of a good thing? Tim-3 and TCR signaling in T cell exhaustion. J. Immunol. 193, 1525-1530 (2014).
15. Chen, D. S., Irving, B. A. & Hodi, F. S. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 18, 6580-6587 (2012).
16. Mu, C. Y. et al. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med. Oncol. 28, 682-688 (2011).
17. Song, M. et al. PTEN loss increases PD-L1 protein expression and affects the correlation between PD-L1 expression and clinical parameters in colorectal cancer. PLoS One 8, e65821 (2013).
18. Konishi, J. et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin. Cancer Res. 10, 5094-5100 (2004).
19. D'Incecco, A. et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer 112, 95-102 (2015).
20. Vassilakopoulou, M. et al. Evaluation of PD-L1 expression and associated tumor-infiltrating lymphocytes in laryngeal squamous cell carcinoma. Clin. Cancer Res. 22, 704-713 (2016).
21. Taube, J. M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci. Transl. Med. 4, 127ra137 (2012).
22. Lipson, E. J. et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res 1, 54-63 (2013).
23. Balermpas, P. et al. CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: a multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). Int. J. Cancer 138, 171-181 (2016).
24. Balermpas, P. et al. Tumour-infiltrating lymphocytes predict response to definitive chemoradiotherapy in head and neck cancer. Br J Cancer 110, 501-509 (2014).
25. Kim, B. H. et al. Lysyl-tRNA synthetase (KRS) expression in gastric carcinoma and tumor-associated inflammation. Ann Surg Oncol 21, 2020-2027 (2014).
26. Ang, K. K. et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N. Engl. J. Med. 363, 24-35 (2010).
27. Mirghani, H. et al. Diagnosis of HPV-driven head and neck cancer with a single test in routine clinical practice. Mod. Pathol. 28, 1518-1527 (2015).
28. Osman, A., Hitzler, W. E., Ameur, A. & Provost, P. Differential Expression Analysis by RNA-Seq Reveals Perturbations in the Platelet mRNA Transcriptome Triggered by Pathogen Reduction Systems. PLoS One 10, e0133070 (2015).
29. Barry, M. & Bleackley, R. C. Cytotoxic T lymphocytes: all roads lead to death. Nat. Rev. Immunol. 2, 401-409 (2002).
30. Fridman, W. H., Pages, F., Sautes-Fridman, C. & Galon, J. The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12, 298-306 (2012).
31. Droeser, R. A. et al. Clinical impact of programmed cell death ligand 1 expression in colorectal cancer. Eur. J. Cancer 49, 2233-2242 (2013).
32. Parsa, A. T. et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat. Med. 13, 84-88 (2007).
33. Atefi, M. et al. Effects of MAPK and PI3K pathways on PD-L1 expression in melanoma. Clin. Cancer Res. 20, 3446-3457 (2014).
34. Palazon, A. et al. The HIF-1alpha hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov 2, 608-623 (2012).
35. Noman, M. Z. et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 211, 781-790 (2014).
36. Badoual, C. et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res 73, 128-138 (2013).
37. Thompson, R. H. et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res. 13, 1757-1761 (2007).
38. Hsu, M. C. et al. Increase of programmed death-1-expressing intratumoral CD8 T cells predicts a poor prognosis for nasopharyngeal carcinoma. Mod. Pathol. 23, 1393-1403 (2010).
39. Muenst, S., Hoeller, S., Dirnhofer, S. & Tzankov, A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum. Pathol. 40, 1715-1722 (2009).
40. Badoual, C. et al. Prognostic value of tumor-infiltrating CD4+ T-cell subpopulations in head and neck cancers. Clin. Cancer Res. 12, 465-472 (2006).
41. Miyara, M. et al. Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3high regulatory T cells in humans. Proc Natl Acad Sci USA 112, 7225-7230 (2015).